United States-based Pfizer and Japan-based Astellas Pharma have submitted a supplemental New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Xtandi (enzalutamide), intended for a new indication and granted priority review designation, it was reported yesterday.
If approved, the supplemental NDA is to expand XTANDI's indication to include men with non-metastatic Castration-Resistant Prostate Cancer (CRPC), based on data from the Phase three PROSPER trial. Presently, XTANDI is indicated for the treatment of patients with metastatic CRPC. The FDA grants Priority Review designation to applications for drugs that, if approved, are likely to offer significant improvements in the safety and effectiveness of the treatment of serious conditions when compared to standard applications. Under Priority Review, the US FDA intends to take action on an application within six months of receipt, as compared to ten months under standard review.
The PROSPER trial assessed the product and androgen deprivation therapy compared with ADT alone in 1,401 patients with non-metastatic CRPC.
The FDA approved XTANDI in 2012 for the treatment of patients with metastatic CRPC who had previously received docetaxel. In 2014, the FDA approved XTANDI to treat patients with metastatic CRPC.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial